1. At a Glance – IVF, IPO & India’s Baby Boom Ambitions
Gaudium IVF & Women Health Ltd is hitting Dalal Street with a ₹165 crore book-built issue at a price band of ₹75–₹79. At the upper band, the company commands a pre-IPO market cap of ₹575.02 crore and trades at a post-IPO P/E of 22.99x based on FY25 numbers. PAT margin? A juicy 25%+. EBITDA margin? A clinic-like sterile 38–40%. ROE recently cooled from 41% (Mar 2025) to 21% (Sep 2025), but still healthy. Debt-to-equity stands at 0.38.
Subscription so far? 1.62x overall by Day 2. Retail investors are enthusiastic at 2.33x, NIIs are playing along at 2.13x, while QIBs are still warming up at 0.01x (Ex-Anchor). Anchor investors already pumped in ₹49.50 crore.
Question is simple: Is this India’s fertility goldmine or just another emotional sector riding optimism?
Let’s examine.
2. Introduction – IVF is Not a Trend, It’s a Demographic Reality
Infertility is no longer whispered about. It’s discussed openly, medically treated aggressively, and commercially scaled efficiently.
Gaudium IVF, incorporated in March 2015, has grown into a 30+ location network using a hub-and-spoke model. Seven hubs. Twenty-eight spokes. Prime city presence — Delhi, Mumbai (Khar West), Bangalore, Patna, Srinagar, Ludhiana.
They serve not just Indian patients but medical tourists from Canada, UK, USA, Kenya, South Africa and Oman. That’s not just treatment. That’s cross-border fertility logistics.
Services include IVF, ICSI, IUI, ovulation induction, PCOS/PCOD treatment, high-risk pregnancy management, and advanced sperm retrieval.
Now pause.
Margins above 38%. PAT margin above 25%. This is not a low-margin hospital chain.
But are we paying too much for growth?
3. Business Model – WTF Do They Even Do?
Imagine this.
One large IVF centre (hub) houses advanced labs like INTEGRA Ti for ICSI. Around it, multiple spokes operate as smaller centres that refer complex cases back to hubs.
This keeps capex relatively lower. Asset-light structure. Higher throughput. Better margins.
Revenue streams include:
- IVF cycles
- ICSI procedures
- IUI treatments
- Gynaecological care
- Male infertility treatments
- High-risk pregnancy services
The expansion plan? ₹50 crore towards new IVF centres. ₹20 crore for debt repayment.
So IPO
